Argenx agreed to acquire Forte Biosciences in an all-cash transaction valued at approximately $2.2 billion. The offer price of $77 per share represents a 40.5% premium over Forte’s last closing price.
The acquisition secures Forte’s lead asset, FB102, which is a first-in-class anti-CD122 antibody. This candidate targets multiple autoimmune diseases.
The transaction signals continued M&A momentum within the biotechnology sector. This activity provides a positive valuation indicator for biotech-focused ETFs including XBI and ARKG as larger firms deploy capital for innovative assets.